January 2026 Research Update

This month, studies of cholesteatoma-related surgery mostly pointed in the same direction: surgeons are testing ways to lower the chance of cholesteatoma coming back while also improving healing and daily symptoms. The clearest signal was that adding mastoid and epitympanic obliteration (filling the space) with S53P4 bioactive glass during canal-wall-up surgery was linked to fewer recurrences over years of follow-up. Other studies focused on how to rebuild ear canal or eardrum tissues after surgery, with reports of good short-term healing and patient-reported improvement, but with less certainty because there were no matched comparison groups or follow-up was short. [1] [2] [3] [4] [5]

In a cohort of 172 ears, canal-wall-up tympano-mastoidectomy with S53P4 bioactive glass obliteration had lower cholesteatoma recidivism than surgery without obliteration (5% vs 18%), and it also had higher 5-year disease-free survival. For patients, this specifically speaks to the long-term concern of cholesteatoma returning after surgery, although the study was retrospective and does not prove why outcomes differed. [1]

Reconstruction studies reported that healing of ear canal skin defects using xenogeneic acellular dermal matrix (a processed tissue scaffold) reached complete epithelialization in about 36 days, with 100% ear canal patency and mostly stable or improved hearing during about 6 months of follow-up. The same report noted common mild drainage and occasional partial membrane loss that was managed by reapplying the material, with rare infection and no rejection reported, but there was no control group to compare against standard care. [2]

Quality-of-life results after cholesteatoma surgery were also reported in a small group of 25 adults, where symptom and life-impact scores improved from before surgery to 3 months after surgery, while measured hearing showed only a trend toward improvement. Complications occurred in 24% of patients, most commonly graft perforation, which helps set expectations that recovery can include setbacks even when overall symptoms improve. [3]

Two additional surgical reports provide context for specific situations rather than general cholesteatoma care. In concha-type microtia with congenital ear canal narrowing, external ear canal cholesteatoma was found in 4 of 60 stenotic ears (6.7%), and after excision plus canal widening there was mild re-narrowing but no recurrence over at least 2 years. A separate study of subtotal eardrum perforation repair (not limited to cholesteatoma) found a less invasive graft approach had shorter operations and less pain, with similar short-term graft success, illustrating how technique choices can affect recovery experience. [4] [5]

For patients, the main practical message this month is that research is steadily focusing on two goals after cholesteatoma surgery: reducing the chance the disease returns and improving healing and day-to-day symptoms. The strongest longer-term data here was the lower recurrence reported with S53P4 bioactive glass obliteration during canal-wall-up surgery, which may matter most to people worried about needing repeat operations, but it still comes from one center and a retrospective comparison. The repair-material and quality-of-life studies may matter now mainly as reassuring early evidence that many people heal well and often feel better after surgery, while also showing that follow-up and complications can still be part of the story; these reports do not by themselves settle which approach is best for an individual. [1] [2] [3]

This month added early pieces to the question of why cholesteatoma develops and why it may behave differently across people and ages. A German case-control study reported that an ABCC11 gene variant was more common in adults with cholesteatoma than in matched controls, supporting a possible inherited risk factor. Separately, a very small tissue gene-expression study suggested pediatric cholesteatoma samples showed higher activity in pathways related to inflammation and tissue remodeling, hinting that children may have different underlying biology than adults. [6] [7]

In the genetic study of 164 adult cholesteatoma cases and 164 controls, the rs17822931 variant in ABCC11 was linked with higher odds of having cholesteatoma under two genetic models. This does not mean the variant causes cholesteatoma by itself, but it supports the idea that inherited factors may contribute to risk alongside infections, anatomy, and other exposures. [6]

In the tissue sequencing study (3 pediatric and 3 adult samples), 14 genes differed between pediatric and adult cholesteatoma, and pediatric samples showed higher activity in TNF-alpha, TGF-beta, and epithelial-mesenchymal transition pathways (signals related to inflammation and scar-like changes). Because the sample was very small, this is best seen as an early clue that could help explain why pediatric disease sometimes seems more active, rather than a settled explanation. [7]

For patients and caregivers, these studies mainly add understanding rather than changing care right now. The genetic finding may matter later if multiple studies confirm it and show how it interacts with other risk factors, potentially helping explain why cholesteatoma appears in some people and not others. The pediatric-versus-adult tissue results may matter in the future by supporting age-specific research, but they are too small to use for predicting an individual child's course today. [6] [7]

Two studies explored ways to improve cholesteatoma treatment beyond standard surgery, but both are at an early stage. In a small human feasibility report, intraoperative autofluorescence helped distinguish cholesteatoma from nearby tissues in real time, which could someday support more complete removal. In mice, a laboratory study reported that the menin-MLL inhibitor BMF-219 reduced experimentally induced cholesteatoma growth, pointing to a possible future non-surgical approach, but this does not yet predict benefits in people. [8] [9]

Autofluorescence imaging was tested in 6 people during cholesteatoma surgery, and the authors reported that cholesteatoma could be visually separated from bone, granulation tissue, and mucosa using a specific light excitation. The practical meaning is that surgeons may eventually have an added visual cue during operations, but the study was small and did not report whether this changes recurrence or hearing outcomes. [8]

In a mouse model, topical BMF-219 was reported to reduce cholesteatoma volume and to lower markers related to cell growth, with no middle ear mucosa or inner ear damage reported in this short evaluation. This supports the idea that cholesteatoma growth might be influenced by specific growth-control pathways, but safety and effectiveness for people remain unknown, especially regarding longer-term ear toxicity. [9]

For patients, this section is mainly about what may be possible in the future rather than what changes now. Autofluorescence imaging could eventually help surgeons identify cholesteatoma more clearly during an operation, but it has only been tested in a handful of patients without outcome comparisons. The mouse drug study raises the possibility of targeted, non-surgical treatments someday, but it is still early laboratory work and needs much more testing before it can be considered relevant to routine patient care. [8] [9]

One study this month was not about cholesteatoma surgery itself, but it touched cholesteatoma through a serious complication pathway: facial nerve palsy linked to ear disease. The audit found that discharge summaries for ENT-related facial palsy often included basic eye lubrication instructions but frequently left out critical details like corneal status and ophthalmology referral. This matters because missing information can make it harder for patients and caregivers to understand follow-up needs during a period when the eye can be vulnerable. [10]

Across 104 discharge summaries, only 8.7% were rated excellent and 60.6% were rated inadequate based on guideline elements, with corneal status documented in 24.0% and ophthalmology referral in 38.5%. Chronic suppurative otitis media with cholesteatoma was the most common listed cause of the facial palsy in this group (40.5%), showing why ear conditions can overlap with eye-protection needs when the facial nerve is affected. [10]

For patients and caregivers, this study points to a care-communication gap rather than a new test or treatment. It suggests that when facial palsy happens alongside ear disease, written discharge instructions may not always capture the full set of eye-safety steps and follow-up plans, which can create confusion after leaving the hospital. The study did not measure whether missing documentation led to worse eye outcomes, so the main contribution is highlighting an area where future quality-improvement work could make care easier to navigate. [10]